
Celsion Corp (NASDAQ:CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock.
Zacks analyst David Bautz highlighted the business update Celsion provided at the end of March. The company announced that following a pre-planned interim safety review of patients in the Phase 1/2 OVATION 2 study of GEN-1 in advanced stage ovarian cancer, the data safety monitoring board unanimously recommended that patients continue to be treated in the study.